EFG Asset Management North America Corp. Sells 6,038 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

EFG Asset Management North America Corp. lessened its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 37.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,196 shares of the company’s stock after selling 6,038 shares during the period. EFG Asset Management North America Corp.’s holdings in Krystal Biotech were worth $1,264,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Krystal Biotech by 40.7% in the third quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after purchasing an additional 693,852 shares during the period. Jennison Associates LLC increased its holdings in Krystal Biotech by 112.5% in the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock valued at $89,862,000 after buying an additional 383,495 shares during the period. First Turn Management LLC acquired a new position in shares of Krystal Biotech in the 4th quarter valued at approximately $30,045,000. Fred Alger Management LLC lifted its holdings in shares of Krystal Biotech by 4,608.6% during the 3rd quarter. Fred Alger Management LLC now owns 167,485 shares of the company’s stock worth $19,428,000 after acquiring an additional 163,928 shares during the period. Finally, TimesSquare Capital Management LLC lifted its holdings in shares of Krystal Biotech by 103.6% during the 4th quarter. TimesSquare Capital Management LLC now owns 250,470 shares of the company’s stock worth $31,073,000 after acquiring an additional 127,435 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on KRYS shares. William Blair restated an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Stifel Nicolaus restated a “buy” rating and set a $204.00 price objective (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Guggenheim boosted their target price on Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Citigroup increased their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Krystal Biotech in a report on Monday, May 6th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Krystal Biotech presently has an average rating of “Buy” and a consensus price target of $171.00.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock traded up $0.59 during trading on Thursday, hitting $163.78. The company’s stock had a trading volume of 159,467 shares, compared to its average volume of 353,009. The stock has a market cap of $4.68 billion, a price-to-earnings ratio of 87.60 and a beta of 0.91. Krystal Biotech, Inc. has a 52 week low of $86.03 and a 52 week high of $189.97. The stock has a 50-day moving average price of $167.93 and a two-hundred day moving average price of $135.77.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.17). The firm had revenue of $45.25 million during the quarter, compared to the consensus estimate of $47.37 million. The company’s revenue for the quarter was up 452400.0% on a year-over-year basis. During the same period last year, the firm posted ($1.76) earnings per share. On average, equities analysts predict that Krystal Biotech, Inc. will post 2.06 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CAO Kathryn Romano sold 8,087 shares of Krystal Biotech stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $136.91, for a total value of $1,107,191.17. Following the completion of the transaction, the chief accounting officer now directly owns 12,556 shares of the company’s stock, valued at approximately $1,719,041.96. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,087 shares of company stock worth $6,210,591. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).